Rexulti lowers dementia-related neuropsychiatric and agitation symptoms in late-stage trial
The analyses revealed that Rexulti was linked to reductions in both overall neuropsychiatric symptoms and agitation symptoms when…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
25 Mar 24
The analyses revealed that Rexulti was linked to reductions in both overall neuropsychiatric symptoms and agitation symptoms when…
25 Mar 24
The label expansions are for the prevention of heart attacks and cardiovascular procedures in primary as well as…
25 Mar 24
Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases
25 Mar 24
The team are seeking to create ‘LungVax’, the world’s first vaccine to prevent lung cancer in people with…
22 Mar 24
LENZ Therapeutics to debut on Nasdaq under the ticker symbol “LENZ” as a publicly traded company advancing late…
15 Mar 24
The accelerated approval was based on the findings from the ongoing Phase 3 MAESTRO-NASH trial in which Rezdiffra…
15 Mar 24
The FDA has approved Breyanzi to treat adult patients with relapsed or refractory chronic lymphocytic leukemia or small…
15 Mar 24
The approval was based on the results from the Phase 3 RATIONALE 302 study in which Tevimbra indicated…
15 Mar 24
As a part of this collaboration, Biocon Biologics will continue to leverage Eris’ strong commercial footprint to significantly…
14 Mar 24
The approval of the IBAT inhibitor was based on findings from the Phase 3 MARCH study which included…